Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 08 2023
21 08 2023
Historique:
received:
07
11
2022
accepted:
14
08
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Many molecular targeted agents, including biologics, have emerged for inflammatory bowel diseases (IBD), but their high prices have prevented their widespread use. This study aimed to reveal the changes in patient characteristics and the therapeutic strategies of IBD before and after the implementation of biologics in Japan, where the unique health insurance system allows patients with IBD and physicians to select drugs with minimum patient expenses. The analysis was performed using a prospective cohort, including IBD expert and nonexpert hospitals in Japan. In this study, patients were classified into two groups according to the year of diagnosis based on infliximab implementation as the prebiologic and biologic era groups. The characteristics of therapeutic strategies in both groups were evaluated using association analysis. This study analyzed 542 ulcerative colitis (UC) and 186 Crohn's disease (CD). The biologic era included 53.3% of patients with UC and 76.2% with CD, respectively. The age of UC (33.9 years vs. 38.8 years, P < 0.001) or CD diagnosis (24.3 years vs. 31.9 years, P < 0.001) was significantly higher in the biologic era group. The association analysis of patients with multiple drug usage histories revealed that patients in the prebiologic era group selected anti-tumor necrosis factor (TNF)-α agents, whereas those in the biologic era group preferred biologic agents with different mechanisms other than anti-TNF-α. In conclusion, this study demonstrated that both patient characteristics and treatment preferences in IBD have changed before and after biologic implementation.
Identifiants
pubmed: 37604846
doi: 10.1038/s41598-023-40624-5
pii: 10.1038/s41598-023-40624-5
pmc: PMC10442357
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Biological Products
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13555Informations de copyright
© 2023. Springer Nature Limited.
Références
N Engl J Med. 2017 May 4;376(18):1723-1736
pubmed: 28467869
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):702-710
pubmed: 32879465
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Digestion. 2023;104(4):328-334
pubmed: 36893744
J Gastroenterol Hepatol. 2012 Aug;27(8):1266-80
pubmed: 22497584
Gastroenterology. 1999 May;116(5):1029-34
pubmed: 10220494
Gastroenterology. 2021 Jun;160(7):2496-2508
pubmed: 34051983
Gastroenterology. 2015 Feb;148(2):344-54.e5; quiz e14-5
pubmed: 25448924
Neurol Med Chir (Tokyo). 2017 Jan 15;57(1):1-7
pubmed: 27666154
Clinicoecon Outcomes Res. 2021 Feb 25;13:145-153
pubmed: 33658813
Gastroenterology. 2020 Apr;158(5):1450-1461
pubmed: 31945371
Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10
pubmed: 31112238
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
Lancet. 2022 Jun 11;399(10342):2200-2211
pubmed: 35691323
Mayo Clin Proc. 2018 Jul;93(7):857-866
pubmed: 29801777
Gut. 2017 May;66(5):839-851
pubmed: 26893500
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):312-321
pubmed: 30659247
J Gastroenterol. 2021 Jun;56(6):489-526
pubmed: 33885977
J Gastroenterol Hepatol. 2020 Mar;35(3):380-389
pubmed: 31596960
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014
pubmed: 34688373
Gastroenterol Hepatol (N Y). 2021 Apr;17(4 Suppl 4):3-13
pubmed: 34135718
N Engl J Med. 2009 Nov 19;361(21):2066-78
pubmed: 19923578
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
Lancet. 1993 Jul 17;342(8864):173-4
pubmed: 8101267
Inflamm Bowel Dis. 2018 Mar 19;24(4):725-731
pubmed: 29548010
Nat Rev Gastroenterol Hepatol. 2017 May;14(5):269-278
pubmed: 28144028
Eur Respir J. 2019 Nov 14;54(5):
pubmed: 31413164